ライフサイエンスコーパス: blood eosinophil

1 tions of type 2 biomarkers (eg, periostin or blood eosinophils).

2 he early glucocorticoid-induced reduction in blood eosinophils.

3 nd decreased IL-5 and eotaxin receptors than blood eosinophils.

4 acerbations did not increase with increasing blood eosinophils.

5 ren based on the molecular patterns of their blood eosinophils.

6 reduced levels of allergen-specific IgE and blood eosinophils.

7 phosphorylation after IL-5 priming of human blood eosinophils.

8 se, and adherence to fibronectin relative to blood eosinophils.

9 at CD127 is present in highly purified human blood eosinophils.

10 putum and this may be reflected by increased blood eosinophils.

11 inhibitory receptor (IR) expressed on human blood eosinophils.

12 changes at 8 weeks in lung function, FeNO or blood eosinophils.

13 alysis in a CCR3(+) eosinophil cell line and blood eosinophils.

14 These subjects also displayed higher blood eosinophils (0.65 vs 0.39, P = 0.021), higher Frac

15 Blood eosinophils (10(9) x l(-1)), bronchial inflammatio

16 Baseline: IgE, 307 +/- 133 Kmu; total blood eosinophils, 296 +/- 149 cells/muL; body mass inde

17 ving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per muL or greater (intentio

18 tients with severe, uncontrolled asthma with blood eosinophils 300 cells per muL or greater.

19 Baseline: IgE, 332 +/- 243 Kmu; total blood eosinophils, 304 +/- 266 cells/muL; body mass inde

20 Among all participants with COPD, blood eosinophils above versus below 0.34 x 10(9) cells

21 ied subjects who demonstrated low peripheral blood eosinophils accompanied by increased expression of

22 Blood eosinophils adhering to adsorbed periostin were im

23 d ERK1/2 phosphorylation observed in primary blood eosinophils after priming with IL-3/GM-CSF, and sm

24 When compared with blood eosinophils, airway eosinophils exhibited greater

25 Blood eosinophils alone were not a reliable biomarker fo

26 The increase in blood eosinophil and basophil counts during high-dose as

27 Blood eosinophil and basophil levels increased and urina

28 Blood eosinophil and C-reactive protein levels were also

29 icant associations, Feno levels, IgE levels, blood eosinophil and neutrophil counts, FEV1 percent pre

30 c asthma with accuracy comparable to that of blood eosinophils and Fe(NO).

31 or associations between activation states of blood eosinophils and features of asthma are reviewed he

32 of control, and markers of TH2 inflammation (blood eosinophils and fraction of exhaled nitric oxide).

33 cs with mepolizumab significantly attenuated blood eosinophils and increased EoP numbers consistent w

34 ilization were conducted in human peripheral blood eosinophils and mouse bone marrow-derived eosinoph

35 thma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemost

36 ne asthma (EPA) phenotype and the utility of blood eosinophils and plasma IL-6 as predictive biomarke

37 Mepolizumab attenuated baseline blood eosinophils and their activation, attenuated trend

38 t, smoking status, use of airway medication, blood eosinophils, and immunoglobulin E (adjusted OR [aO

39 stitutively active in freshly isolated human blood eosinophils, and inhibition of Notch signaling or

40 uated aeroallergen sensitization, peripheral blood eosinophils, and serum periostin as potential biom

41 ing treatment effects in relation to FE(NO), blood eosinophils, and serum periostin at baseline.

42 93.8%), and 534 (62.8%) patients for FE(NO), blood eosinophils, and serum periostin, respectively.

43 Moreover, the combination of Fe(NO), blood eosinophils, and VOCs gave a very good prediction

44 Elevated numbers of blood eosinophils are a risk factor for asthma exacerbat

45 Whether high blood eosinophils are associated with chronic obstructiv

46 ion values for eotaxin-induced chemotaxis of blood eosinophils are in the low nanomolar range.

47 greater exacerbation frequency, and whether blood eosinophils are predictive of sputum eosinophils.

48 life aeroallergen sensitization and elevated blood eosinophils are robust predictors of asthma develo

49 his review was to summarize the evidence for blood eosinophils as a predictive biomarker for corticos

50 We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an

51 opoietin receptor was observed on peripheral blood eosinophils as well as on tissue infiltrating eosi

52 EoE treatment, association of platelets with blood eosinophils, as reported by CD41, predicted esopha

53 We recorded blood eosinophils at baseline and future COPD exacerbati

54 ol, lung function, bronchial responsiveness, blood eosinophils, atopy and treatment level were assess

55 ce in distinguishing eosinophilic N-ERD (for blood eosinophils, AUC = 0.72; for periostin, AUC = 0.75

56 sinophils from the circulation requires that blood eosinophils become activated, leading to their arr

57 ction of exhaled nitric oxide (Feno) values, blood eosinophil (bEOS) counts, serum CCL26 expression,

58 Before anti-IL-5, surface densities of blood eosinophil beta(2) , alpha(M) and alpha(L) integri

59 In the SARP-3 multivariable model, blood eosinophils, body mass index, and bronchodilator r

60 76/88 (86%) had normal blood eosinophils, but of these, 84% had airway eosinoph

61 In addition, allergic sensitization and blood eosinophils can be used to select medications for

62 Blood eosinophil cell counts predicted srT2-high asthma

63 The decrease of CRTH2 on blood eosinophils clearly correlated with disease activi

64 benralizumab-treated patients with baseline blood eosinophil concentrations of 200 cells per muL or

65 We also analysed whether blood eosinophil concentrations reliably predicted sputu

66 marker-positive and -negative exacerbations (blood eosinophil count > and </= 2%, respectively).

67 hilic phenotype were stratified according to blood eosinophil count (>/=150 per cubic millimeter at s

68 % and >/=3%, and <5% and >/=5%) and absolute blood eosinophil count (<150 cells/mul, 150 to <300 cell

69 ith pneumonia events, stratified by baseline blood eosinophil count (<2% vs >/=2% of blood leucocytes

70 x life-threatening exacerbations with median blood eosinophil count (5-95th percentiles) of 0.270 x 1

71 FeNO, airway responsiveness, blood eosinophil count (B-Eos) and IgE sensitization to

72 Fraction of exhaled nitric oxide (Feno) and blood eosinophil count (B-Eos) values, markers of local

73 st total serum IgE level (median, 733 kU/L), blood eosinophil count (median, 400 cells/mm(3)), and al

74 tion of IL-6 (non-Type 2 asthma) and FeNO or blood eosinophil count (Type 2 asthma) identified asthma

75 randomly allocated them (1:1; stratified by blood eosinophil count [<300 cells per muL vs >/=300 cel

76 shown a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizu

77 We investigated the relation between blood eosinophil count and prospective annual asthma out

78 The most well established of these are the blood eosinophil count and serum periostin, both of whic

79 of the IMPACT trial shows that assessment of blood eosinophil count and smoking status has the potent

80 gressively with nine ascending categories of blood eosinophil count as compared with a reference cate

81 matching placebo was given according to the blood eosinophil count biomarker.

82 ife-threatening asthma, we found that a spot blood eosinophil count correlates with severity of respi

83 Blood eosinophil count could potentially be used to stra

84 e relationship between observed efficacy and blood eosinophil count for moderate or severe exacerbati

85 the previous 12 months, and had a screening blood eosinophil count greater than or equal to 1000 cel

86 c significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma

87 g inhaled corticosteroids (ICS) and baseline blood eosinophil count in patients with chronic obstruct

88 the asthma symptoms worsened and peripheral blood eosinophil count increased to 813/muL.

89 condition did not improve and her peripheral blood eosinophil count increased.

90 Blood eosinophil count is a promising biomarker of respo

91 The peripheral blood eosinophil count is a promising biomarker to direc

92 We investigated whether blood eosinophil count is a useful biomarker of the long

93 eroid treatment for COPD have shown that the blood eosinophil count is associated with the risk of CO

94 fit 1 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/muL subgroup

95 vilanterol was 0.88 (95% CI 0.74 to 1.04) at blood eosinophil count less than 90 cells per muL and 0.

96 Blood eosinophil count mediated 29% of the life-course-p

97 than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the

98 0.48, 0.39-0.58) in patients with a baseline blood eosinophil count of at least 150 cells per muL to

99 In METREO, all patients had a blood eosinophil count of at least 150 per cubic millime

100 persistent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microli

101 patients and among subgroups with a baseline blood eosinophil count of less than 150 cells/muL, basel

102 assessed the trends and correlations between blood eosinophil count on admission with arterial blood

103 flares (worsening of HES-related symptoms or blood eosinophil count requiring therapeutic escalation)

104 f asthma symptoms and reduced the peripheral blood eosinophil count to 0/muL.

105 The mean blood eosinophil count was 200/muL (SD, 144/muL).

106 maximum of up to 4 days) on days when their blood eosinophil count was at least 0.3 x 10(9) cells pe

107 An elevated blood eosinophil count when asthma is stable predicts ex

108 The T2 phenotype was defined by using a blood eosinophil count with a threshold of 300 cells/muL

109 assessed on the basis of total IgE level and blood eosinophil count) and serum periostin level.

110 iomarker measurements (Fe(NO) and peripheral blood eosinophil count).

111 pred of 75.1%, median values of 300/mm(3) of blood eosinophil count, 323 kU/L of serum total IgE, and

112 ht to determine the relationship between the blood eosinophil count, clinical characteristics and gen

113 e exacerbations increased in proportion with blood eosinophil count, compared with a non-ICS dual lon

114 The combination of blood eosinophil count, fractional exhaled nitric oxide,

115 neous lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histolo

116 ificant positive association with the linear blood eosinophil count, whereas in U-BIOPRED, 1197 genes

117 To elucidate the relationship between a spot blood eosinophil count-measured at the onset of a life-t

118 xacerbations was independent of the baseline blood eosinophil count.

119 a prespecified subgroup analysis by baseline blood eosinophil count.

120 blood counts, and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cel

121 At baseline, patients with blood eosinophil counts >=150 cells/uL (or >=300 cells/u

122 sly increased Feno levels (>/=20-25 ppb) and blood eosinophil counts (>/=0.3 x 10(9)/L) had a higher

123 ients with mild-to-moderate asthma with high blood eosinophil counts (>=300 cells/muL).

124 re, <20) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01).

125 il counts or singly increased Feno levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%,

126 exhaled nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/muL) than all other gr

127 hase were evaluated with respect to baseline blood eosinophil counts (eosinophils <300/muL [low] vs >

128 a (odds ratio, 32.6; P = 6.9 x 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 x 10(-

129 nts and subjects with normal Feno levels and blood eosinophil counts (P = .02) after adjusting for co

130 Increased peripheral blood eosinophil counts (patients with EG: 1.09 +/- 0.88

131 correlation found was between IgE levels and blood eosinophil counts (r = 0.33, P < .001); furthermor

132 Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per muL or greater and

133 re, a count-response relation exists between blood eosinophil counts and asthma-related outcomes.

134 ant association between sputum or peripheral blood eosinophil counts and body mass index.

135 To assess the relationship between baseline blood eosinophil counts and efficacy of mepolizumab we d

136 Clinical studies reveal changes in blood eosinophil counts and eosinophil cationic proteins

137 irin reactions correlated with reductions in blood eosinophil counts and lung function and increases

138 i-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatm

139 number of controller medications, and total blood eosinophil counts and negatively with the Asthma C

140 Blood eosinophil counts and smoking status could be impo

141 subjects with both increased Feno levels and blood eosinophil counts and subjects with normal Feno le

142 each on serum immunoglobulin E (IgE) levels, blood eosinophil counts and three on lung function as me

143 cationic protein in nasal washes, along with blood eosinophil counts and total and allergen-specific

144 sone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in

145 gion, screening periostin concentration, and blood eosinophil counts as covariates.

146 hial brushings transcriptional signal versus blood eosinophil counts as well as differential expressi

147 ults were observed in patients regardless of blood eosinophil counts at enrollment.

148 267 in the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per muL and w

149 Blood eosinophil counts at screening were related to the

150 bations was found among patients with higher blood eosinophil counts at screening.

151 Elevated blood eosinophil counts combined with clinical character

152 Blood eosinophil counts could add predictive value to Gl

153 s to determine whether an algorithm based on blood eosinophil counts could safely reduce systemic cor

154 asthma with recurrent exacerbations and high blood eosinophil counts despite use of inhaled corticost

155 Patients with asthma and blood eosinophil counts greater than 400 cells per muL e

156 verall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per muL.

157 eroids, 40 (3.8%) patients with less than 2% blood eosinophil counts had a pneumonia event versus 48

158 s a threshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than d

159 p between genes and pathways associated with blood eosinophil counts in asthma versus COPD.

160 in urinary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolera

161 ght to investigate increased Feno levels and blood eosinophil counts in relation to lung function, br

162 notyping with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment

163 vidence that patients with COPD and baseline blood eosinophil counts less than 2% have a poorer respo

164 At blood eosinophil counts less than 90 cells per muL and a

165 Blood eosinophil counts might predict response to inhale

166 less than 2% and 6818 patients had baseline blood eosinophil counts of 2% or more.

167 Patients with baseline blood eosinophil counts of 220 cells per muL or greater

168 ren with both aeroallergen sensitization and blood eosinophil counts of 300/muL or greater.

169 are odds of asthma control for patients with blood eosinophil counts of 400 cells per muL or less ver

170 AER among patients with baseline blood eosinophil counts of at least 0 cells per muL was

171 Patients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per muL an

172 symptom score at week 48, for patients with blood eosinophil counts of at least 300 cells per muL.

173 in 1 s (FEV1 in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per

174 4043 patients had baseline blood eosinophil counts of less than 2% and 6818 patient

175 on of exhaled nitric oxide (Feno) levels and blood eosinophil counts offer additive information in re

176 No differences were documented in blood eosinophil counts or serum markers after eHF intak

177 evere BHR than having normal Feno levels and blood eosinophil counts or singly increased Feno levels

178 Having increased Feno levels and blood eosinophil counts related to a higher prevalence o

179 comparisons of symptoms, lung function, and blood eosinophil counts revealed differences that were m

180 Blood eosinophil counts showed a positive relationship w

181 Blood eosinophil counts showed a weak but significant as

182 ificantly higher total IgE levels and higher blood eosinophil counts than those with the lower-risk g

183 LRTSs and blood eosinophil counts were augmented and lung function

184 Measurements of Feno levels and blood eosinophil counts were available in 406 subjects (

185 aire 5 score was reduced by 0.47 points, and blood eosinophil counts were reduced by 78%, with simila

186 lizumab in patients with asthma and elevated blood eosinophil counts who are inadequately controlled

187 ssess whether patients with COPD with higher blood eosinophil counts would be more likely to have exa

188 ment eosinophil-derived neurotoxin levels or blood eosinophil counts).

189 very severe airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations

190 etermine the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric

191 EV1, PC20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment d

192 ic inflammation, including serum IgE levels, blood eosinophil counts, and tissue eosinophil counts.

193 levels, and FEV1 percent predicted, but not blood eosinophil counts, correctly predicted 69% of sput

194 Intraepithelial peak eosinophil and blood eosinophil counts, esophageal-related symptoms, se

195 We sought to determine whether blood eosinophil counts, Feno levels, and IgE levels acc

196 ociation with sputum eosinophil percentages, blood eosinophil counts, Feno levels, and total IgE leve

197 in patients with increased serum IgE levels, blood eosinophil counts, or both were also negative.

198 mab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eo

199 gnificantly greater than AUCs for peripheral blood eosinophil counts, sputum neutrophil counts, and c

200 Variables, such as blood eosinophil counts, total IgE levels, fraction of e

201 For 2665 patients with elevated blood eosinophil counts, treatment effect with benralizu

202 ures of gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with

203 re examined, patients with elevated baseline blood eosinophil counts, with three or more exacerbation

204 ho received placebo, independent of baseline blood eosinophil counts.

205 L) and 1237 with high (>/=200 cells per muL) blood eosinophil counts.

206 ith severe, uncontrolled asthma and elevated blood eosinophil counts.

207 h life-course-persistent asthma had elevated blood eosinophil counts.

208 n Asthma Control Questionnaire 5 scores, and blood eosinophil counts.

209 d fractional polynomials to model continuous blood eosinophil counts.

210 In patients with a baseline blood eosinophil cutoff of at least 300 cells per muL, e

211 Blood eosinophils demonstrate circadian cycling, as desc

212 Although high blood eosinophils did not occur in EPA, the incident rat

213 atient experienced an increase in peripheral blood eosinophils during the clinical course and receive

214 Human blood eosinophils exhibit a hyperactive phenotype in res

215 Human blood eosinophils exposed ex vivo to hematopoietic cytok

216 analysis, we previously observed that human blood eosinophils express mRNA for IL-7R alpha (CD127) a

217 Siglec-7 was expressed ex vivo on blood eosinophils from all eosinophilic and normal indiv

218 Blood eosinophils from children and adults with EoE, and

219 Siglec-8 is highly expressed on blood eosinophils from EOs and NDs and represents a pote

220 The high blood eosinophil group had slightly increased airway wal

221 significantly different between low and high blood eosinophil groups, but differences were less than

222 s as well as differential expression using a blood eosinophil > 200 cells/muL as a cut-off.

223 rker-high patients (periostin >/=50 ng/mL or blood eosinophils >/=300 cells per muL), analysed with a

224 were followed-up over a median of 52 months, blood eosinophils >=1.200 x 10(9) /L was associated with

225 2-high asthma (subgroups including baseline blood eosinophils >=150/300 cells/uL and/or fractional e

226 improvement by AZD9412 in patients with high blood eosinophils (>0.3 x 10(9) /L) at screening and low

227 y corticosteroid response and the biomarker 'blood eosinophils' has emerged as an attractive candidat

228 RATIONALE: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomark

229 airway hyperresponsiveness, more airway and blood eosinophils, higher serum IgE, more subepithelial

230 monia event versus 48 (2.4%) with 2% or more blood eosinophils (HR 1.53; 95% CI 1.01-2.31).

231 ssification performance similar to Fe(NO) or blood eosinophils in eosinophilic asthma.

232 ing in GM-CSF-primed transmigration of human blood eosinophils in vitro and in the airway accumulatio

233 IL-5 activates alpha(M) beta(2) integrin on blood eosinophils in vitro.

234 r Lyn before cytokine (IL-5/IL-3) priming of blood eosinophils inhibited the synergistic increase of

235 Blood eosinophil KIM-127 reactivity at the time of chall

236 5), more frequent exacerbations (P = .0042), blood eosinophil level less than or equal to 100 cells/m

237 th COPD in the general population, increased blood eosinophil levels above 0.34 x 10(9) cells per lit

238 aled a direct correlation between peripheral blood eosinophil levels and B cell numbers.

239 In patients with allergic asthma, baseline blood eosinophil levels and/or clinical markers of asthm

240 However, normal blood eosinophil levels did not exclude airway eosinophi

241 ts over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.

242 t signal tagged by rs992969 associating with blood eosinophil levels, asthma, and eosinophilic asthma

243 exhaled nitric oxide (<35 and >=35 ppb) and blood eosinophil (<250 and >=250 cells/uL) subgroups.

244 neously increased local (Feno) and systemic (blood eosinophil) markers of type 2 inflammation related

245 examined by flow cytometry using peripheral blood eosinophils, mast cell lines, and Siglec-8-transdu

246 tudies have examined the prognostic value of blood eosinophils measured at exacerbation.

247 try for age, asthma duration, lung function, blood eosinophil measurement, ACQ-6 scores, and diabetes

248 of this study were to determine whether the blood eosinophil molecular pattern of children with EoE

249 them had bronchiectasis, and 20.9% had <100 blood eosinophils/mul.

250 the Global Initiative for Asthma guidelines, blood eosinophil numbers are one marker that helps to gu

251 ficient mice exhibited diminished peripheral blood eosinophil numbers at baseline.

252 uding sex, age, body mass index, IgE levels, blood eosinophil numbers, Feno levels, and serum periost

253 led corticosteroid based therapy and who had blood eosinophils of 400 cells per muL or higher and one

254 ncontrolled eosinophilic asthma and baseline blood eosinophils of at least 300 cells per muL, possibl

255 Severe asthma patients with high blood eosinophils or low serum interleukin-18 response a

256 (P < 0.05), plasma tryptase (P < 0.01), and blood eosinophil (P < 0.01) and basophil (P < 0.01) coun

257 dicators of TH2-like inflammation, including blood eosinophils (P = .001), exhaled nitric oxide (P =

258 atopy (IgE positive to >/= 1 allergen), and blood eosinophil percent (dichotomized at the median) we

259 We compared treatment efficacy according to blood eosinophil percentage (<2% and >/=2%, <3% and >/=3

260 d airway wall eosinophil counts (P = 0.003), blood eosinophil percentage (P = 0.03), bronchodilator r

261 age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and higher treat

262 n of exhaled nitric oxide (Feno), peripheral blood eosinophil, periostin, YKL-40, and IgE levels and

263 ar patterns may partly explain the different blood eosinophil phenotypes in children vs adults with E

264 Forward scatter of blood eosinophils post-challenge was less heterogeneous

265 Blood eosinophil progenitors (EoPs) correlate with tissu

266 muL, and >/=500 cells per muL) and baseline blood eosinophil ranges (<150 cells per muL, >/=150 cell

267 Blood eosinophil reactivity with monoclonal antibody (mA

268 l activation of beta1 and beta2 integrins on blood eosinophils, reported by monoclonal antibodies (mA

269 dependent eosinophil cytolysis of IL3-primed blood eosinophils seeded on heat-aggregated immunoglobul

270 with elevated baseline levels of peripheral blood eosinophils, serum IgE, or periostin exhibited a g

271 baseline fractional exhaled nitric oxide and blood eosinophil subgroups (207 mL [95% CI: -283, 698];1

272 ime to exacerbation outcomes on the basis of blood eosinophil subgroups of increasing cutoff levels.

273 baseline fractional exhaled nitric oxide and blood eosinophil subgroups, respectively) and were susta

274 In contrast, using a cutpoint of 2% for blood eosinophils, the risk of exacerbations was increas

275 combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/muL or greater o

276 of 150 cells/muL or greater or a historical blood eosinophil threshold of 300 cells/muL or greater w

277 cebo for patients with a combination of high blood eosinophil thresholds and a history of more freque

278 lizumab for patients with different baseline blood eosinophil thresholds and exacerbation histories.

279 rates were reduced increased with increasing blood eosinophil thresholds and with greater exacerbatio

280 , stratifying patients by different baseline blood eosinophil thresholds.

281 Investigate the usefulness of blood eosinophils to direct corticosteroid therapy durin

282 better biomarker than high concentrations of blood eosinophils to identify a patient subgroup with mo

283 In contrast to the transfer of untreated blood eosinophils to the lungs of recipient eosinophil d

284 Ras activation by FMLP in blood eosinophils was also enhanced following IL-5 primi

285 hibitory receptor CD300a in human peripheral blood eosinophils was investigated.

286 Human peripheral blood eosinophils were activated by SEB with or without

287 (2+) -flux and apoptosis of human peripheral blood eosinophils were assessed in vitro.

288 Isolated blood eosinophils were incubated on glass coverslips coa

289 Peripheral blood eosinophils were isolated for the analysis of meta

290 Peripheral blood eosinophils were isolated to assess the effect of

291 Blood eosinophils were measured in the biomarker-directe

292 Peripheral blood eosinophils were obtained from volunteers with ast

293 Human peripheral blood eosinophils were treated with agonistic anti-Sigle

294 Human blood eosinophils were used to establish the impact of a

295 Peripheral blood eosinophils were used to study intracellular signa

296 (FEV1, fraction of exhaled nitric oxide, and blood eosinophils) were assessed over 12 weeks.

297 draining lymph nodes (LDLN), pretreatment of blood eosinophils with GM-CSF prior to transfer elicited

298 lted in the near complete loss of peripheral blood eosinophils with no apparent impact on any other h

299 ere incubated with purified human peripheral blood eosinophils with or without activation in the pres

300 sinophils and GBM, we cultured human primary blood eosinophils with two separate human GBM-derived ce